Com­pu­gen touts ovar­i­an can­cer da­ta in com­bo with Op­di­vo, an­ti-TIG­IT from ex-part­ner Bris­tol My­ers

Com­pu­gen pre­sent­ed a batch of da­ta from ear­ly-stage tri­als of its an­ti-PVRIG can­di­date in dual and triple com­bi­na­tion stud­ies, in­clud­ing one with an an­ti-TIG­IT ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER